Quince Therapeutics, Inc. financial data

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, California
State of incorporation
California
Fiscal year end
December 31
Former names
Cortexyme, Inc. (to 8/1/2022)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.36 K % -39.4%
Debt-to-equity 52.3 % +1081%
Return On Equity -36.8 % +11.5%
Return On Assets -24.2 % +39.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43.2 M shares +19.1%
Common Stock, Shares, Outstanding 43.2 M shares +19.1%
Entity Public Float 50 M USD -28.6%
Common Stock, Value, Issued 43 K USD +19.4%
Weighted Average Number of Shares Outstanding, Basic 43 M shares +20%
Weighted Average Number of Shares Outstanding, Diluted 43 M shares +20%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.92 M USD -36.6%
General and Administrative Expense 18.8 M USD -9.13%
Operating Income (Loss) -32.9 M USD +23.7%
Income Tax Expense (Benefit) 476 K USD
Net Income (Loss) Attributable to Parent -30.3 M USD +28.4%
Earnings Per Share, Basic -0.76 USD/shares +34.5%
Earnings Per Share, Diluted -0.76 USD/shares +34.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.8 M USD -3.49%
Cash, Cash Equivalents, and Short-term Investments 67.8 M USD -24.8%
Other Assets, Current 48 K USD -73.2%
Assets, Current 70.4 M USD -23.8%
Property, Plant and Equipment, Net 234 K USD +3800%
Operating Lease, Right-of-Use Asset 576 K USD +237%
Intangible Assets, Net (Excluding Goodwill) 62.3 M USD
Goodwill 17.2 M USD
Other Assets, Noncurrent 8.47 M USD
Assets 159 M USD +70.7%
Accounts Payable, Current 2.07 M USD +25.4%
Accrued Liabilities, Current 3.02 M USD +106%
Liabilities, Current 9.84 M USD +216%
Deferred Income Tax Liabilities, Net 5.18 M USD
Operating Lease, Liability, Noncurrent 480 K USD
Other Liabilities, Noncurrent 599 K USD
Liabilities 85.1 M USD +2632%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.83 M USD +4703%
Retained Earnings (Accumulated Deficit) -331 M USD -10.1%
Stockholders' Equity Attributable to Parent 74.2 M USD -17.8%
Liabilities and Equity 159 M USD +70.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.35 M USD -134%
Net Cash Provided by (Used in) Financing Activities 190 K USD +280%
Net Cash Provided by (Used in) Investing Activities 8.91 M USD +60.9%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 43.2 M shares +19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06 M USD -50.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.8 M USD -53.3%
Deferred Tax Assets, Valuation Allowance 85.1 M USD +22.1%
Deferred Tax Assets, Gross 97.4 M USD +37.7%
Operating Lease, Liability 573 K USD +113%
Payments to Acquire Property, Plant, and Equipment 39 K USD -71.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.5 M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid 726 K USD +164%
Operating Lease, Liability, Current 93 K USD -65.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 136 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 139 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +51%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 153 K USD +2450%
Lessee, Operating Lease, Liability, to be Paid, Year Three 130 K USD
Deferred Tax Assets, Operating Loss Carryforwards 81.9 M USD +65.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 4.34 M USD +17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 216 K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 12.3 M USD +1089%
Share-based Payment Arrangement, Expense 5.01 M USD -43.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%